High Graphics | Low Graphics
Latest Headlines | Word Search
Comment
Arpida pays for solo strategy as FDA voices serious iclaprim concerns
With the likelihood of Arpida’s antibiotic iclaprim gaining approval next year now looking extremely slim, and only enough funds to last into the second half of 2009, the future of the company is look...
19 Nov 2008
AstraZeneca fights back against Teva's "at risk" launch of generic Pulmicort Subscription Only
News that Teva Pharmaceutical Industries had launched an “at risk” generic version of AstraZeneca’s asthma drug, Pulmicort Respules, pushed shares in the UK pharma giant down sharply, the fall was als...
19 Nov 2008
IDM's good news could be first step to turnaround Subscription Only
A 64% rise in your share price would be enough to warm the heart of any healthcare company chief executive in these difficult markets, and is even more welcome if you have been on the receiving end of...
19 Nov 2008
Closing the door on XTL Biopharmaceuticals Subscription Only
News that XTL Biopharmaceuticals’ bicifadine failed in phase IIb trials to treat pain associated with diabetic neuropathy adds weight to the view this indication is something of a graveyard for drug d...
18 Nov 2008
123
To help you keep up to date with our most recent comment and analysis you can add our RSS feed to your browser. With the RSS feed you will receive instant notification of the new content on our website. You will be able to see the headlines, a brief description of stories and link straight back to EP Vantage.com. What is this? View Archive
Showing headlines from the Past 7 Days
 Retrieving...
Analysis
Event - Green light for Astra's Numax could give investors something to smile about Subscription Only
After yesterday’s slew of bad news including the release of a generic version of its asthma drug, Pulmicort Respules, that caused it to revise its full year guidance, and disappointing trial results f...
20 Nov 2008
Options aplenty for private companies seeking a public listing Subscription Only
Having aborted a $60m IPO attempt in February, Archemix has taken advantage of the massive downturn in pharma and biotech company valuations and achieved its goal of becoming a public company by effec...
20 Nov 2008
Event - Targanta and Theravance face short wait for final FDA decisions
The ongoing FDA anti-infectives advisory committee meeting continued in an unpredictable vein yesterday, with a panel of experts handing down a much more positive review of Theravance’s antibiotic tel...
20 Nov 2008
United's clever use of substitute could give it breathing space Subscription Only
There had been high hopes that United Therapeutic’s oral formulation of pulmonary arterial hypertension (PAH) drug, Remodulin, would have the legs to go all the way to approval by the end of 2010. Unf...
18 Nov 2008
12
To help you keep up to date with our most recent comment and analysis you can add our RSS feed to your browser. With the RSS feed you will receive instant notification of the new content on our website. You will be able to see the headlines, a brief description of stories and link straight back to EP Vantage.com. What is this? View Archive
Showing headlines from the Past 7 Days
 Retrieving...

Related Links

Registered Users

Word Search

Enter your free-text query in the box below